Document:

<Page>

                                                                   EXHIBIT 10.9

                                WARRANT AGREEMENT

                                     between

                          EON LABS MANUFACTURING, INC.,
                                   as Issuer,

                           THE VARIOUS WARRANTHOLDERS
                       WHO ARE OR MAY BECOME PARTY HERETO

                                       and

                           HEXAL PHARMACEUTICALS, INC.

Dated as of December 5, 2000

<Page>

<Table>
<Caption>
                                TABLE OF CONTENTS

                                                                                          Page
                                                                                          ----
<S>            <C>                                                                         <C>
SECTION 1.     Definitions..................................................................1
SECTION 2.     The Warrants.................................................................5
SECTION 3.     Exercise.....................................................................5
SECTION 4.     Payment of Taxes.............................................................7
SECTION 5.     Replacement Warrant..........................................................7
SECTION 6.     Representations and Warranties of the Company................................7
SECTION 7.     Reservation of Shares and Other Covenants....................................7
SECTION 8.     Distributions and Notices...................................................10
SECTION 9.     No Dilution or Impairment...................................................11
SECTION 10.    Registration Rights; Procedures; Indemnification............................12
SECTION 11.    Transfers of the Warrant....................................................17
SECTION 12.    Right of First Refusal in Sales by Security Holders.........................18
SECTION 13.    Come Along..................................................................20
SECTION 14.    Confidentiality.............................................................21
SECTION 15.    Delays, Omissions and Indulgences...........................................21
SECTION 16.    Rights of Transferees.......................................................21
SECTION 17.    Captions....................................................................22
SECTION 18.    Notices.....................................................................22
SECTION 19.    Successors and Assigns......................................................22
SECTION 20.    Severability................................................................22
SECTION 21.    GOVERNING LAW...............................................................22
SECTION 22.    Entire Agreement; Amendment.................................................22
SECTION 23.    Rules of Construction.......................................................23
</Table>

                                       -i-
<Page>

                                WARRANT AGREEMENT

     THIS WARRANT AGREEMENT (the "AGREEMENT") is dated as of December 5, 2000,
among EON LABS MANUFACTURING, INC., a Delaware corporation (the "COMPANY"), each
of the other warrantholders who are or may become party hereto (collectively,
the "WARRANTHOLDERS") and solely for the purposes of Section 13 hereof, HEXAL
PHARMACEUTICALS, INC., a Delaware Corporation ("Hexal").

                              STATEMENT OF PURPOSE

     Pursuant to a Stock and Debt Repayment Purchase Agreement, dated
November __, 2000 (the "PURCHASE AGREEMENT"), among Hexal Pharmaceuticals, Inc.
("HEXAL") and all of the holders (the "ELI STOCKHOLDERS") of all of the capital
stock of, and of warrants to purchase capital stock of, Eon Labs, Inc., a
Delaware corporation ("ELI"), Hexal is purchasing all of the outstanding ELI
capital stock and warrants from the ELI Stockholders, and the ELI Stockholders
are selling to Hexal all of the outstanding ELI capital stock and warrants.

     As a result of the purchase and sale of securities contemplated by the
Purchase Agreement, ELI and the Company will become wholly owned subsidiaries of
Hexal.

     It is a condition to the purchase and sale of securities contemplated by
the Purchase Agreement that the Company issue to the Warrantholders, Stock
Purchase Warrants (the "WARRANTS") to purchase five percent (5%) of the Fully
Diluted (as hereinafter defined) Common Stock of the Company.

     The parties hereto desire to set forth certain terms and conditions
applicable to the Warrants and certain rights and obligations among the Company
and the Warrantholders, as more fully described herein.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as
follows:

     SECTION 1.   DEFINITIONS.

     As used herein, the following terms shall have the following meanings.
Capitalized terms not appearing below and not otherwise defined herein shall
have the meaning ascribed to them in the Purchase Agreement.

     "AFFILIATE" means, with respect to any Person, any other Person directly or
indirectly controlling or controlled by or under direct or indirect common
control with such Person. For purposes of this definition, "control" when used
with respect to any Person means the power to direct the management and policies
of such Person, directly or indirectly, whether through the ownership of voting
securities, by contract or otherwise; and the terms "controlling" and
"controlled" have meanings correlative to the foregoing.

     "AGGREGATE EXERCISE PRICE" has the meaning assigned thereto in
Section 3(b).

<Page>

     "ASSIGNED PERCENTAGE" has the meaning assigned thereto in Section 2.

     "BUSINESS DAY" means a day other than a Saturday, Sunday or other day on
which commercial banks in New York, New York are authorized or required by law
to close.

     "CAPITAL STOCK" means (a) in the case of a corporation, capital stock, (b)
in the case of an association or business entity, any and all shares, interests,
participations, rights or other equivalents (however designated) of capital
stock, (c) in the case of a partnership, partnership interests (whether general
or limited), (d) in the case of a limited liability company, membership
interests and (e) any other interest or participation that confers on a Person
the right to receive a share of the profits and losses of, or distributions of
assets of, the issuing Person.

     "CASHLESS EXERCISE" has the meaning assigned thereto in Section 3(c).

     "CHARTER DOCUMENTS" means the Certificate of Incorporation and the Bylaws
of the Company, as amended or supplemented from time to time.

     "COMMISSION" means the Securities and Exchange Commission or any similar
agency then having jurisdiction to enforce the Securities Act or the Exchange
Act.

     "COMMON STOCK" means (a) the common stock of the Company, par value $0.01
per share, as described in the Charter Documents, and (b) any other Capital
Stock of the Company into which such Common Stock is reclassified or
reconstituted.

     "CURRENTLY OUTSTANDING SHARES" means the shares of Series A Preferred Stock
outstanding on the date of this Agreement.

     "DISPOSITION" has the meaning assigned thereto in Section 13.

     "DISTRIBUTION" has the meaning assigned thereto in Section 8(a).

     "ELECTION TO PURCHASE" has the meaning assigned thereto in Section 3(a).

     "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission thereunder.

     "EXERCISE AMOUNT" has the meaning assigned thereto in Section 3(a).

     "EXERCISE PRICE" has the meaning assigned thereto in Section 2.

     "EXPIRATION DATE" means the earliest of (a) the fifth (5th) anniversary of
the date hereof, (b) the Initial Public Offering or (c) the Sale of the Company.

     "FAIR MARKET VALUE PER SHARE" means as of a particular date (a) the fair
market value of the Fully Diluted Common Stock based upon an arm's length sale
of the Company on such date (including its ownership interest in all Persons) as
an entirety, such sale being between a willing buyer and a willing seller and
determined without reference to any discount for minority interest, restrictions
on transfer, disparate voting rights among classes of Capital Stock or lack of

                                       -2-
<Page>

marketability with respect to capital stock DIVIDED BY (b) the aggregate number
of shares of Fully Diluted Common Stock. The Fair Market Value Per Share shall
be determined initially by the Company within ten (10) days of any event for
which such determination is required and such determination (including the basis
therefor) shall be promptly provided to each Warrantholder. Such determination
shall be binding on each Warrantholder unless the Required Warrantholders object
thereto in writing within ten (10) days of receipt. In the event the Company and
the Required Warrantholders cannot agree on the Fair Market Value Per Share
within ten (10) Business Days of receipt by the Company of the Required
Warrantholders' objection, the Fair Market Value Per Share shall be determined
by an appraiser that is not an Affiliate of any interested party (which may be a
national or regional investment bank or national accounting firm) mutually
selected by the Company and the Required Warrantholders; PROVIDED, that if the
Company and the Required Warrantholders shall fail to agree to such an
appraiser, the Fair Market Value Per Share shall be determined by a panel of
three such appraisers. Within five (5) days after the date the Company and the
Required Warrantholders determine that they cannot agree as to an appraiser, the
Company on the one hand and the Required Warrantholders on the other hand shall
each designate one such appraiser that is willing and able to conduct such
determination. If either fails to make such determination within such time
period, then the other parry that has made the designation shall have the right
to make the designation on such failing party's behalf. The two appraisers so
designated shall, within a period of five (5) days after the designation of the
second appraiser, designate a mutually acceptable third appraiser. The Fair
Market Value Per Share shall be the average of the determination of the two
appraisers that are closer to each other than to the determination of the third
appraiser, which third determination shall be discarded; PROVIDED, HOWEVER, that
if the determination of two appraisers are equally close to the determination of
the third appraiser, then the Fair Market Value Per Share shall be the average
of the determination of all three appraisers. The fees and expenses of the
appraisers shall be paid by the Company unless such determination results in a
Fair Market Value Per Share less than or equal to the Fair Market Value Per
Share initially determined by the Company in which case such fees and expenses
shall be borne by the Warrantholders. Any determination of Fair Market Value Per
Share by the appraiser or appraisers shall be made within thirty (30) days of
the date of selection of the last appraiser (if there shall be more than one).

     "FULLY DILUTED" means, with respect to the Common Stock, as of any date,
the number of shares of Common Stock that would be outstanding assuming all
securities of the Company convertible into or exchangeable for Common Stock
(including, without limitation, shares of Series A Preferred Stock) were
converted into shares of Common Stock pursuant to their respective terms and all
options, warrants or other rights to acquire Common Stock were exercised.

     "HEXAL SELLER" has the meaning assigned thereto in Section 13.

     "INITIAL PUBLIC OFFERING" by the Company shall be deemed to have occurred
on the date of the closing of the first sale by the Company to the general
public of its Capital Stock in a transaction registered under the Securities Act
pursuant to a Securities Act registration statement that is effective under the
Securities Act.

     "PERCENTAGE INTEREST" means, with respect to any Warrantholder, the
quotient, expressed as a percentage, equal to (a) the number of Warrant Shares
for which such Warrantholder's

                                       -3-
<Page>

Warrant may be exercised divided by (b) the aggregate number of Warrant Shares
for which all Warrants may be exercised.

     "PERMITTED HEXAL TRANSFEREE" has the meaning assigned thereto in
Section 13.

     "PERSON" means any individual, firm, corporation, partnership, limited
liability company, joint venture, association, joint stock company, trust,
unincorporated organization or government or any agency or political subdivision
thereof, or other entity of any kind and includes any successor (by merger or
otherwise) of such entity.

     "PRINCIPAL OFFICE" means the Company's principal office as set forth in
Section 18 hereof or such other principal office of the Company in the United
States of America the address of which first shall have been set forth in a
notice to the Warrantholders.

     "PURCHASE AGREEMENT" has the meaning assigned thereto in the Statement of
Purpose.

     "REGISTRATION EXPENSES" shall mean the expenses so described in
Section 10(c) hereof.

     "REGULATORY REQUIREMENT" has the meaning assigned thereto in Section 6(c).

     "REQUIRED WARRANTHOLDERS" means the holders of at least fifty-one percent
(51%) of the Warrant Securities then outstanding determined on a Fully Diluted
basis.

     "SALE OF THE COMPANY" means the sale, lease or disposition of all or
substantially all of the outstanding capital stock, assets or business of the
Company to a third party which is not an Affiliate of the Company or, the
merger, consolidation or share exchange of the Company with or into another
corporation which is not an Affiliate of the Company.

     "SECURITIES ACT" means the Securities Act of 1933, as amended, and the
rules and regulations of the Commission thereunder.

     "SELLING EXPENSES" shall mean the expenses so described in Section 10(c)
hereof.

     "SERIES A PREFERRED STOCK" means the Company's Series A Convertible
Preferred Stock, par value $.01 per share.

     "SUBSIDIARY" means, with respect to any Person, any entity of which more
than fifty percent (50%) of the outstanding capital stock or other ownership
interests having ordinary voting power to elect the board of directors or other
managers of such entity is at the time, directly or indirectly, owned by or the
management is otherwise controlled by such Person. Unless otherwise qualified,
references to "Subsidiary" or "Subsidiaries" herein shall refer to those of the
Company.

     "THIRD PARTY TRANSFEREE" has the meaning assigned thereto in Section 13.

     "TRANSACTION" has the meaning assigned thereto in Section 8(b).

                                       -4-
<Page>

     "VOTING STOCK" means, with respect to any Person, Capital Stock issued by
such Person the holders of which are ordinarily, in the absence of
contingencies, entitled to vote for the election of directors (or persons
performing similar functions) of such Person, even though the right so to vote
has been suspended by the happening of such a contingency.

     "WARRANT" has the meaning assigned thereto in the Statement of Purpose.

     "WARRANT SHARES" means (a) the shares of Common Stock issued or issuable
upon exercise of any Warrant in accordance with its terms, and (c) all other
shares of the Capital Stock issued with respect to such shares by way of stock
dividend, stock split or other reclassification or in connection with any
merger, consolidation, recapitalization or other reorganization affecting the
Company's Capital Stock.

     SECTION 2.   THE WARRANTS.

     Pursuant to the Purchase Agreement and subject to the terms and conditions
of this Agreement, the Company hereby issues and delivers to the Warrantholders
Warrants (each in the form of EXHIBIT A hereto) to purchase, at a price per
share equal to $.01 per share (the "EXERCISE PRICE"), fully paid and
nonassessable shares of Common Stock. Prior to the earlier of an Initial Public
Offering or the Sale of the Company, each Warrant shall be exercisable for a
number of shares of Common Stock which will represent, at the time of exercise
of the Warrant, a specified percentage (as indicated on Schedule 1.2 to the
Purchase Agreement for the specified Warrantholder) of the total number of
shares of the Company's Common Stock on a Fully Diluted basis not exceeding in
the aggregate for all Warrants, five percent (5%) of the Fully Diluted Common
Stock (such Warrant's "ASSIGNED PERCENTAGE"). As of the date of this Agreement,
the Warrants are exercisable, in the aggregate for shares of the Company's
Common Stock which represent five percent of the Fully Diluted Common Stock.

     SECTION 3.   EXERCISE.

     (a)   METHOD OF EXERCISE. On or before the Expiration Date, each
Warrantholder, in accordance with the terms hereof, may exercise its Warrant in
whole or in part. Each Warrantholder shall effect such exercise by delivering
such Warrant to the Company during normal business hours on any Business Day at
the Company's Principal Office, together with the Election to Purchase, in the
form attached hereto as EXHIBIT B (the "ELECTION TO PURCHASE"), duly executed,
and payment of the Exercise Price per share for the number of shares to be
purchased (the "EXERCISE AMOUNT"), as specified in the Election to Purchase. If
the Expiration Date is not a Business Day, then such Warrant may be exercised on
the next succeeding Business Day.

     (b)   PAYMENT OF AGGREGATE EXERCISE PRICE. Payment of the Aggregate
Exercise Price shall be made to the Company in cash or other immediately
available funds or as provided in Section 3(c), or a combination thereof. In the
case of payment of all or a portion of the Aggregate Exercise Price pursuant to
Section 3(c), the direction by the exercising Warrantholder to make a Cashless
Exercise shall serve as accompanying payment for that portion of the Aggregate
Exercise Price. The amount to be paid (the "AGGREGATE EXERCISE PRICE") shall
equal the product of (a) the Exercise Amount multiplied by (b) the Exercise
Price.

                                       -5-
<Page>

     (c)   CASHLESS EXERCISE. Each exercising Warrantholder shall have the right
to pay all or a portion of the Aggregate Exercise Price by making a cashless
exercise pursuant to this Section 3(c) (a "CASHLESS EXERCISE"), in which case
the portion of the Aggregate Exercise Price to be so paid shall be paid by
reducing the number of shares of Common Stock otherwise issuable pursuant to the
Election to Purchase by an amount equal to the product of (A)(i) the Exercise
Price to be so paid divided by (ii) the Fair Market Value Per Share and (B) the
number of shares of Common Stock otherwise issuable pursuant to the Election to
Purchase. Upon a Sale of the Company or the consummation of an Initial Public
Offering, in each case prior to the fifth (5th) anniversary of the date hereof,
each Warrantholder shall automatically be deemed to have made a Cashless
Exercise immediately prior to the Sale of the Company or the consummation of an
Initial Public Offering, as the case may be, notwithstanding that a duly
executed Election to Purchase, the remaining Exercise Amount (if any) and the
Warrant shall not have been tendered to the Company; PROVIDED, HOWEVER, until
such tender, such Warrantholder shall not be entitled to receive certificates
representing the shares of Common Stock issuable upon such exercise. The number
of shares of Common Stock to be issued to the exercising Warrantholder as a
result of a Cashless Exercise will therefore be as follows:

       (FAIR MARKET VALUE PER SHARE-EXERCISE PRICE) x Cashless Exercise Amount*
                        Fair Market Value Per Share

     * The Cashless Exercise Amount in the above formula is that portion of the
       Exercise Amount (expressed as a number of shares of Common Stock) with
       respect to which the Exercise Price is being paid by Cashless Exercise
       pursuant to this Section 3(c).

     (d)   ISSUANCE OF SHARES. Upon receipt by the Company of the exercising
Warrantholder's Warrant at its Principal Office in proper form for exercise, and
accompanied by payment of the Aggregate Exercise Price as aforesaid, or upon an
automatic Cashless Exercise upon a Sale of the Company or the consummation of
the Initial Public Offering pursuant to Section 3(c), the exercising
Warrantholder shall be deemed to be the holder of record of the share of Common
Stock issuable upon such exercise, notwithstanding that certificates
representing such shares of Common Stock may not then be actually delivered.
Upon such surrender of such Warrant and payment of the Aggregate Exercise Price
as aforesaid, the Company shall issue and cause to be delivered with all
reasonable dispatch to, or upon the written order of, such Warrantholder (and in
such name or names as such Warrantholder may designate) a certificate or
certificates for the Exercise Amount, subject to any reduction as provided in
Section 3(c) for a Cashless Exercise.

           FRACTIONAL SHARES. The Company shall not be required to deliver
fractions of shares of Common Stock upon exercise of any Warrant. If any
fraction of a share of would be deliverable upon exercise of a Warrant, the
Company may, in lieu of delivering such fraction of a share, make a cash payment
to the affected Warrantholder in an amount equal to the same fraction of the
Fair Market Value Per Share determined as of the Business Day immediately
preceding the date of exercise of such Warrant.

                                       -6-
<Page>

     (e)   PARTIAL EXERCISE. In the event of a partial exercise of any Warrant,
the Company shall issue to the affected Warrantholder a Warrant in like form for
the unexercised portion thereof.

     SECTION 4.   PAYMENT OF TAXES.

     The Company shall pay all stamp taxes attributable to the initial issuance
of shares or other securities issuable upon the exercise of each Warrant or
issuable pursuant to Section 8 hereof, excluding any tax or taxes which may be
payable because of the transfer involved in the issuance or delivery of any
certificates for shares or other securities in a name other than that of the
exercising Warrantholder in respect of which such shares or securities are
issued.

     SECTION 5.   REPLACEMENT WARRANT.

     If any Warrant is mutilated, lost, stolen or destroyed, the Company shall
issue and deliver in exchange and substitution for and upon cancellation of the
mutilated Warrant, or in lieu of and in substitution for the Warrant lost,
stolen or destroyed, a new Warrant of like tenor and representing an equivalent
right or interest, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction of such Warrant and upon receipt
of indemnity reasonably satisfactory to the Company; PROVIDED, that if the
Warrantholder is a financial institution or other institutional investor its own
agreement shall be satisfactory.

     REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and
warrants to each Warrantholder as follows:

     (a)   The execution, delivery and performance of this Agreement by the
Company have been duly authorized by all requisite corporate action and will not
violate any provision of law, any order of any court or other agency of
government, the Charter Documents of the Company, or any provision of any
indenture, agreement or other instrument to which it or any of its properties or
assets is bound, or conflict with, result in a breach of or constitute (with due
notice or lapse of time or both) a default under any such indenture, agreement
or other instrument, or result in the creation or imposition of any lien, charge
or encumbrance of any nature whatsoever upon any of the properties or assets of
the Company or any of its Subsidiaries.

     (b)   This Agreement has been duly executed and delivered by the Company
and constitutes the legal, valid and binding obligation of the Company,
enforceable in accordance with its terms.

     SECTION 6.   RESERVATION OF SHARES AND OTHER COVENANTS.

     (a)   RESERVATION OF AUTHORIZED COMMON STOCK. The Company shall at all
times reserve and keep available out of the aggregate of its authorized but
unissued shares, free of preemptive rights, such number of its duly authorized
shares of Common Stock, or other stock or securities deliverable pursuant to
Section 8 hereof, as shall be sufficient to enable the Company at any time to
fulfill all of its obligations under this Agreement and the Warrants.

     (b)   AFFIRMATIVE ACTIONS TO PERMIT EXERCISE AND REALIZATION OF BENEFITS.
If any shares of Common Stock reserved or to be reserved for the purpose of
exercise of the Warrants, or any

                                       -7-
<Page>

shares or other securities reserved or to be reserved for the purpose of
issuance pursuant to Section 8 hereof, require registration with or approval
(other than as a result of a Regulatory Requirement contemplated by
Section 6(c)) of any governmental authority under any federal or state law
(including but not limited to approvals or expirations of waiting periods
required under the Hart-Scott-Rodino Antitrust Improvements Act, but excluding
the Securities Act and any state securities or "blue skies" laws) before such
shares or other securities may be validly delivered upon exercise of any
Warrant, then each of the Company and the Warrantholders shall cooperate with
each other so that each may prepare and file notification and report forms in
compliance with such law and shall otherwise fully comply with the requirements
of such law, to the extent required in connection with the exercise of the
Warrants. The Warrantholders shall bear all filing fees and their own legal
expenses in connection with the filing of such forms.

     (c)   REGULATORY REQUIREMENTS AND RESTRICTIONS. In the event of any
reasonable determination by any Warrantholder that, by reason of any existing or
future federal or state law, statute, rule, regulation, guideline, order, court
or administrative ruling, request or directive (whether or not having the force
of law and whether or not failure to comply therewith would be unlawful) (a
"REGULATORY REQUIREMENT"), such Warrantholder is effectively restricted or
prohibited from holding its Warrant or the related Warrant Shares (including any
shares of capital stock or other securities distributable to such Warrantholder
in any merger, reorganization, readjustment or other reclassification), or
otherwise realize upon or receive the benefits intended under its Warrant, the
Company shall, and shall use its commercially reasonable efforts to have its
shareholders, take such action as such Warrantholder may reasonably deem
necessary to permit such Warrantholder to comply with such Regulatory
Requirement. Such action to be taken may include, without limitation, the
Company's authorization of one or more new classes of Capital Stock for which
such Warrant may be exercised or to make such modifications and amendments to
the Charter Documents, this Agreement, the related Warrant or any other
documents and instruments related to or executed in connection herewith or with
the Warrants as may be deemed reasonably necessary by such Warrantholder. Such
Warrantholder shall give written notice to the Company of any such determination
and the action or actions necessary to comply with such Regulatory Requirement,
which notice and determination shall be conclusive absent manifest error, and
the Company shall take all commercially reasonable steps necessary to comply
with such determination as expeditiously as possible.

     (d)   VALIDLY ISSUED SHARES. The Company covenants that all shares of
Capital Stock that may be delivered upon exercise of each Warrant (including
those issued pursuant to Section 8 hereof) shall upon delivery by the Company be
duly authorized and validly issued, fully paid and nonassessable, free from all
taxes, liens and charges with respect to the issue or delivery thereof and
otherwise free of all other security interests, encumbrances and claims of any
nature whatsoever.

     (e)   SALE OR TRANSFER OF ASSETS. The Company covenants that it shall not,
and it shall not permit any of its Subsidiaries to, sell, lease or transfer or
otherwise dispose of any or all of its assets to any Person (other than the
sale, lease or transfer from the Company to any wholly-owned Subsidiary of the
Company, or from any Subsidiary of the Company to the Company or any other
wholly-owned Subsidiary of the Company) other than the sale of assets or
inventory, in

                                       -8-
<Page>

each case in the ordinary course of business to the extent consistent with the
operations of the Company as conducted prior to the date of this Agreement.

     (f)   TRANSACTION WITH AFFILIATES. Then Company covenants that it shall
not, and that it shall not permit any of its Subsidiaries to, effect any
transaction with any Affiliates (other than transactions between the Company and
any of its wholly-owned Subsidiaries and transactions between or among
wholly-owned Subsidiaries of the Company) on a basis less favorable to the
Company and its Subsidiaries, considered as a whole, than would be the case if
such transaction had been effected with a Person not an Affiliate.

     (g)   ISSUANCE OF CAPITAL STOCK. Then Company covenants that prior to its
Initial Public Offering it shall not issue or agree to issue any shares of its
Capital Stock (nor shall it issue or agree to issue any security of any kind
evidencing a right to subscribe for and receive or which is otherwise
exercisable for or convertible into or exchangeable for) shares of any class of
the Company's Capital Stock other than shares of the Company's Common Stock;
provided, however, that this provision shall not be deemed to be breached by the
Company having outstanding the Currently Outstanding Shares.

     (h)   FINANCIAL STATEMENTS. The Company will deliver to the holders of
Warrant Securities:

           (i)    within 120 days after the end of each fiscal year of the
Company, audited consolidated balance sheets of the Company and its Subsidiaries
and related statements of income, stockholders' equity and cash flows as of the
end of and for such year, setting forth in each case in comparative form the
figures for the previous fiscal year, all reported on by the Company's
independent public accountants to the effect that such consolidated financial
statements present fairly in all material respects the financial condition and
results of operations of the Company and its Subsidiaries on a consolidated
basis in accordance with generally accepted accounting principles consistently
applied;

           (ii)   within 60 days after the end of each of the first three fiscal
quarters of each fiscal year of the Company, consolidated balance sheets of the
Company and its Subsidiaries and related statements of operations, stockholders'
equity and cash flows as of the end of and for such fiscal quarter and the then
elapsed portion of the fiscal year, setting forth in each case in comparative
form the figures for the corresponding period or periods of (or, in the case of
the balance sheet, as of the end of) the previous fiscal year, all certified by
the chief financial officer, principal accounting officer, treasurer or
controller of the Company as presenting fairly in all material respects the
financial condition and results of operations of the Company and its
Subsidiaries on a consolidated basis in accordance with generally accounting
principles consistently applied, subject only to normal year-end audit
adjustments and the absence of footnotes.

     (i)   RULE 144 REPORTING. The Company covenants as follows:

           (i)    The Company shall make and keep public information available
as those terms are understood and defined in Rule 144 under the Securities Act,
at all times from and after 90 days following its Initial Public Offering.

                                       -9-
<Page>

           (ii)   The Company shall file with the Commission in a timely manner
all reports and other documents as the Commission may prescribe under Section
13(a) or 15(d) of the Exchange Act at any time after the Company has become
subject to such reporting requirements of the Exchange Act.

           (iii)  The Company shall furnish to each holder of Warrant Securities
forthwith upon request (x) a written statement by the Company as to its
compliance with the reporting requirements of Rule 144 (at any time from and
after 90 days following its Initial Public Offering), and of the Securities Act
and the Exchange Act (at any time after it has become subject to such reporting
requirements), (y) a copy of the most recent annual or quarterly report of the
Company, and (z) such other reports and documents so filed as such holder may
reasonably request to avail itself of any rule or regulation of the Commission
allowing a holder of Warrant Shares to sell any such securities without
registration.

     SECTION 7.   DISTRIBUTIONS AND NOTICES.

     (a)   CERTAIN DISTRIBUTIONS. In case at any time or from time to time prior
to the Company's Initial Public Offering the Company shall set a record date of
the holders of any class or series of its capital stock for the purpose of
entitling them to receive any dividend or other distribution (collectively, a
"Distribution") of:

           (A)    cash (other than the following dividends (collectively, the
                  "Excluded Distributions"): (1) a single dividend in an amount
                  not to exceed $10,000,000 in the aggregate payable not later
                  than 30 days following the Closing Date and (2) subsequent
                  dividends all of which together shall aggregate not more than
                  $40 million, but only to the extent that any such dividend
                  described in clause (1) or (2) of this Section 8(a)(A) is used
                  by Hexal not later than the Business Day next following the
                  date of payment of any such dividend to make a payment or
                  prepayment on the Note (as defined in the Purchase Agreement)
                  in a matching amount),

           (B)    any (x) evidences of its Indebtedness, or (y) other securities
                  or property of any nature whatsoever (other than cash or
                  shares of the Company's capital stock), or

           (C)    any options, warrants or other rights to subscribe for or
                  purchase any of the following: any (x) evidences of
                  Indebtedness, or (y) other securities or property of any
                  nature whatsoever (other than shares of Capital Stock),

then each Warrantholder shall be entitled to receive upon the exercise of its
Warrant(s) at any time on or after such record date, the number of Warrant
Shares to be received upon exercise of such Warrant(s) determined as stated
herein and, in addition and without further payment, the net amount (after
giving effect to any equity infusions made by the Company's stockholders) of
cash, evidences of Indebtedness, stock, securities, other property, options,
warrants and/or other rights (or any portion thereof) to which such
Warrantholder would have been entitled by way of such Distribution and
subsequent dividends and distributions through the date of exercise as if such
Warrantholder (I) had exercised its Warrant(s) immediately prior to such
Distribution and

                                      -10-
<Page>

(II) had retained the Distribution and all subsequent dividends and
distributions of any nature whatsoever in respect of any stock or securities
paid as dividends and distributions and originating directly or indirectly from
such Distribution. It is the intent of the parties (x) that each Warrantholder
shall not receive any of the Excluded Distributions and (y) to amend promptly
after the Closing Date, Section A of Article Fourth of the Company's Certificate
of Incorporation by adding the following sentence after the first sentence of
such Section A: "The holders of Common Stock shall not be entitled to
participate with the holders of Preferred Stock in any dividends paid or set
aside for payment to the Preferred Stock unless the resolution authorizing such
dividend shall so expressly provide." Each Warrantholder hereby irrevocably
waives the right to receive the Excluded Distributions, whether or not he or it
is then a holder of Warrant Shares. Each Warrantholder agrees to take all action
reasonably requested by the Company to implement the intent of this waiver and
the proposed amendment to the Company's Certificate of Incorporation.

     (b)   NOTICE OF PROPOSED ACTIONS. In case the Company shall propose (A) to
pay any dividend payable in stock of any class to the holders of its Common
Stock or to make any other distribution (whether in stock, cash, property,
evidences of indebtedness or other securities) to the holders of its Common
Stock, (B) to offer to the holders of its Common Stock rights to subscribe for
or to purchase any Convertible Securities or additional shares of Common Stock
or shares of stock of any class or any other securities, warrants, rights or
options, (C) to effect any reclassification of its Common Stock, (D) to effect
any recapitalization, stock subdivision, stock combination or other capital
reorganization, (E) to effect any consolidation or merger, share exchange, or
sale, lease or other disposition of all or substantially all of its property,
assets or business or any other Sale of the Company or (F) to effect the
liquidation, dissolution or winding up of the Company, then in each such case
the Company shall give to each Warrantholder written notice of such proposed
action, which shall specify the record date for the purposes of such stock
dividend, distribution or rights, or the date on which such reclassification,
reorganization, consolidation, merger, share exchange, sale, transfer,
disposition, Sale of the Company, liquidation, dissolution or winding up is to
take place and the date of participation therein by the holders of Common Stock,
if any such date is to be fixed, or the date on which the transfer of Common
Stock is to occur, and shall also set forth such facts with respect thereto as
shall be reasonably necessary to indicate the effect of such action on the
Common Stock. Such notice shall be so given in the case of any action covered by
clause (A) or (B) above at least fifteen (15) days prior to the record date for
determining holders of the Common Stock for purposes of such action and, in the
case of any other such action, at least fifteen (15) days prior to the earlier
of the date of the taking of such proposed action or the date of participation
therein by the holders of Common Stock.

     SECTION 8.   NO DILUTION OR IMPAIRMENT.

     The Company will not, by amendment of its Charter Documents or through any
reorganization, recapitalization, transfer of assets, consolidation, merger,
share exchange, dissolution or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of any Warrant,
including without limitation the terms of Section 8 hereof, and will at all
times in good faith assist in the carrying out of all such terms and in taking
of all such action as may be necessary or appropriate to protect the rights of
the Warrantholder against dilution or other impairment. Without limiting the
generality of the foregoing and

                                      -11-
<Page>

notwithstanding any other provision of any Warrant to the contrary (including by
way of implication), the Company (a) will not increase the par value of any
shares of Common Stock receivable on the exercise of any Warrant above the
amount payable therefor on such exercise and (b) will take all such corporate
action as may be necessary or appropriate so that the Company may validly and
legally issue fully paid and nonassessable shares of Common Stock on the
exercise of any Warrant.

     SECTION 9.   REGISTRATION RIGHTS; PROCEDURES; INDEMNIFICATION.

     (a)   INCIDENTAL REGISTRATION. If the Company at any time proposes to
register any of its securities under the Securities Act for sale to the public,
whether for its own account or for the account of other security holders or both
(except with respect to registration statements on Form S-8 or another form not
available for registering Warrant Shares for sale to the public), each such time
it will give written notice to all holders of Warrant Securities of its
intention to do so. Upon the written request of any such holder, given within 20
days after the date of any such notice, to register any of its Warrant Shares
(which request shall state the intended method of disposition thereof), the
Company will use its best efforts to cause the Warrant Shares as to which
registration shall have been so requested to be included in the securities to be
covered by the registration statement proposed to be filed by the Company, all
to the extent requisite to permit the sale or other disposition by the holder
(in accordance with its written request) of such Warrant Shares so registered.
The Company may withdraw any such registration statement before it becomes
effective or postpone the offering of securities contemplated by such
registration statement without any obligation to the holders of any Warrant
Shares. In the event that any registration pursuant to this Section 10(a) shall
be an underwritten public offering of Common Stock, a holder may be excluded
from the underwriting if such holder does not agree to the terms of the
underwriting. The number of shares of Common Stock, including, without
limitation Warrant Shares, to be included in such an underwriting may be reduced
if and to the extent that the managing underwriter shall be of the opinion that
such inclusion would adversely affect the marketing of the securities to be sold
by the Company therein; PROVIDED, HOWEVER, that if any shares are to be included
in such underwriting for the account of any person other than the Company, the
number of shares to be included by any such person shall be reduced first. With
respect to the proviso of the preceding sentence, if the Company elects to
reduce the amount of Warrant Shares proposed to be offered in the underwriting
for the accounts of all persons other than the Company, such reduction shall be
PRO RATA among all such persons (other than the Company) and, for purposes of
making any such reduction, each holder of Warrant Shares which is a partnership,
together with the affiliates, partners, employees, retired partners and retired
employees of such holder, the estates and family members of any such partners,
employees, retired partners and retired employees and of their spouses, and any
trusts for the benefit of any of the foregoing persons shall be deemed to be a
single "person," and any PRO RATA reduction with respect to such "person" shall
be based upon the aggregate number of Warrant Shares owned by all entities and
individuals included as such "person", as defined in this sentence (and the
aggregate number so allocated to such "person" shall be allocated among the
entities and individuals included in such "person" in such manner as such holder
of Warrant Shares may reasonably determine). Notwithstanding anything to the
contrary contained in this Section 10(a), if requested by the Company and its
underwriter, each Warrantholder and holder of Warrant Shares shall not sell or
otherwise transfer or dispose of any Common Stock (or other securities) of the
Company held by it (other than those included in the registration) during a
period not to

                                      -12-
<Page>

exceed a 180 day period following the effective date of the Company's
registration statement in the case of the Company's Initial Public Offering,
provided that all officers, directors and Affiliates of the Company (who own the
Capital Stock of the Company) and each holder of more than 1% of the outstanding
Common Stock of the Company shall enter into similar agreements.

     (b)   REGISTRATION PROCEDURES. If and whenever the Company is required by
the provisions of Section 10(a) hereof to use its best efforts to effect the
registration of any Warrant Shares under the Securities Act, the Company will,
as expeditiously as possible:

           (i)    prepare and file with the Commission a registration statement
with respect to such securities and use its best efforts to cause such
registration statement to become and remain effective for the period of the
distribution contemplated thereby (determined as hereinafter provided);

           (ii)   prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for
the period specified in Section 10(b)(i) above and as to comply with the
provisions of the Securities Act with respect to the disposition of all Warrant
Shares covered by such registration statement in accordance with the sellers'
intended method of disposition set forth in such registration statement for such
period;

           (iii)  furnish to each seller and to each underwriter such number of
copies of the registration statement and the prospectus included therein
(including each preliminary prospectus) as such persons may reasonably request
in order to facilitate the public sale or other disposition of the Warrant
Shares covered by such registration statement;

           (iv)   use its best efforts to register or qualify the Warrant Shares
covered by such registration statement under the securities or blue sky laws of
such jurisdictions as the sellers of Warrant Shares or, in the case of an
underwritten public offering, the managing underwriter shall reasonably request
provided that the Company would not be required to execute a general consent to
service of process, unless the Company is already subject to service in such
jurisdiction;

           (v)    immediately notify each seller under such registration
statement and each underwriter, at any time when a prospectus relating thereto
is required to be delivered under the Securities Act, of the happening of any
event as a result of which the prospectus contained in such registration
statement, as then in effect, includes an untrue statement of a material fact or
omits to state any material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances
then existing;

           (vi)   use its best efforts to furnish, at the request of any seller,
on the date that Warrant Shares is delivered to the underwriters for sale
pursuant to such registration: (x) an opinion dated such date of counsel
representing the Company for the purposes of such registration, addressed to the
underwriters and to such seller, stating (A) that such registration statement
has become effective under the Securities Act, (B) that, to the best knowledge
of such counsel, no stop order suspending the effectiveness thereof has been
issued and no proceedings for that purpose have been instituted or are pending
or contemplated under the Securities Act and

                                      -13-
<Page>

(C) that the registration statement and the related prospectus, and each
amendment or supplement thereof, comply as to form in all material respects with
the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder (except that such counsel need not express any
opinion as to financial statements contained therein), and to such other effects
as may reasonably be requested by counsel for the underwriters or by such seller
or its counsel, and (y) a letter dated such date from the independent public
accountants retained by the Company, addressed to the underwriters and to such
seller, stating that they are independent public accountants within the meaning
of the Securities Act and that, in the opinion of such accountants, the
financial statements of the Company included in the registration statement or
the prospectus, or any amendment or supplement thereof, comply as to form in all
material respects with the applicable accounting requirements of the Securities
Act, and such letter shall additionally cover such other financial matters
(including information as to the period ending no more than five business days
prior to the date of such letter) with respect to the registration in respect of
which such letter is being given as such underwriters or such seller may
reasonably request; and

           (vii)  make available for inspection by each seller, any underwriter
participating in any distribution pursuant to such registration statement, and
any attorney, accountant or other agent retained by such seller or underwriter,
all financial and other records, pertinent corporate documents and properties of
the Company, and cause the Company's officers, directors and employees to supply
all information reasonably requested by any such seller, underwriter, attorney,
accountant or agent in connection with such registration statement.

     For purposes of Sections 10(b)(i) and (ii) above, the period of
distribution of Warrant Shares in a firm commitment underwritten public offering
shall be deemed to extend until each underwriter has completed the distribution
of all securities purchased by it, and the period of distribution of Warrant
Shares in any other registration shall be deemed to extend until the earlier of
the sale of all Warrant Shares covered thereby or 120 days after the effective
date thereof.

     In connection with each registration hereunder, the selling holders of
Warrant Shares will furnish to the Company in writing such information with
respect to themselves and the proposed distribution by them as shall be
necessary in order to assure compliance with Federal and applicable state
securities laws.

     In connection with each registration pursuant to Section 10(a) hereof
covering an underwritten public offering, the Company agrees to enter into a
written agreement with the managing underwriter selected in the manner herein
provided in such form and containing such provisions as are customary in the
securities business for such an arrangement between major underwriters and
companies of the Company's size and investment stature, provided that such
agreement shall not contain any such provision applicable to the Company which
is inconsistent with the provisions hereof and provided, further, that the time
and place of the closing under said agreement shall be as mutually agreed upon
between the Company and such managing underwriter.

     (c)   EXPENSES. All expenses incurred by the Company in complying with
Section 10(a) hereof, including, without limitation, all registration and filing
fees, printing expenses, fees and disbursements of counsel and independent
public accountants for the Company, fees of the

                                      -14-
<Page>

National Association of Securities Dealers, Inc., transfer taxes, fees of
transfer agents and registrars and costs of insurance, but excluding any Selling
Expenses, are herein called "Registration Expenses". All underwriting discounts
and selling commissions applicable to the sale of Warrant Shares are herein
called "Selling Expenses." The Company will pay all Registration Expenses in
connection with each registration statement filed pursuant to Section 10(a)
hereof. All Selling Expenses incurred in connection with any sale of Warrant
Shares by any participating seller shall be borne by such participating seller,
or by such persons other than the Company (except to the extent the Company
shall be a seller) as they may agree.

     (d)   INDEMNIFICATION. In the event of a registration of any of the Warrant
Shares under the Securities Act pursuant to 10(a) hereof, the Company will
indemnify and hold harmless each seller of such Warrant Shares thereunder and
each underwriter of such Warrant Shares thereunder and each other person, if
any, who controls such seller or underwriter within the meaning of the
Securities Act, against any and all losses, claims, damages, expenses or
liabilities, joint or several, to which such seller or underwriter or
controlling person may become subject under the Securities Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained in any registration statement under
which such Warrant Shares were registered under the Securities Act pursuant to
Section 10(a), any preliminary prospectus or final prospectus contained therein,
or any amendment or supplement thereof, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, and
will reimburse each such seller, each such underwriter and each such controlling
person for any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability, expense
or action; provided, however, that the Company will not be liable in any such
case if and to the extent that any such loss, claim, damage or liability arises
out of or is based upon an untrue statement or alleged untrue statement or
omission or alleged omission so made in conformity with information furnished by
such seller, such underwriter or such controlling person in writing specifically
for use in such registration statement or prospectus.

     In the event of a registration of any of the Warrant Shares under the
Securities Act pursuant to Section 10(a) hereof, each seller of such Warrant
Shares thereunder, severally and not jointly, will indemnify and hold harmless
the Company and each person, if any, who controls the Company within the meaning
of the Securities Act, each officer of the Company who signs the registration
statement, each director of the Company, each underwriter and each person who
controls any underwriter within the meaning of the Securities Act, against all
losses, claims, damages, expenses or liabilities, joint or several, to which the
Company or such officer or director or underwriter or controlling person may
become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages, expenses or liabilities (or actions in respect thereof) arise
out of or are based upon any untrue statement or alleged untrue statement of any
material fact contained in the registration statement under which such Warrant
Shares were registered under the Securities Act pursuant to Section 10(a), any
preliminary prospectus or final prospectus contained therein, or any amendment
or supplement thereof, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the
Company and each such officer, director, underwriter and controlling person for
any legal or

                                      -15-
<Page>

other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability or action; PROVIDED, HOWEVER,
that such seller will be liable hereunder in any such case if and only to the
extent that any such loss, claim, damage or liability arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged
omission made in reliance upon and in conformity with information pertaining to
such seller, as such, furnished in writing to the Company by such seller
specifically for use in such registration statement or prospectus; PROVIDED,
FURTHER, HOWEVER, that the liability of each seller hereunder shall be limited
to the proceeds received by such seller from the sale of Warrant Shares covered
by such registration statement. Promptly after receipt by an indemnified party
hereunder of notice of the commencement of any action, such indemnified party
shall, if a claim in respect thereof is to be made against the indemnifying
party hereunder, notify the indemnifying party in writing thereof, but the
omission so to notify the indemnifying party shall not relieve it from any
liability which it may have to any indemnified party under this Section 10(d).
In case any such action shall be brought against any indemnified party and it
shall notify the indemnifying party of the commencement thereof, the
indemnifying party shall be entitled to participate in and, to the extent it
shall wish, to assume and undertake the defense thereof with counsel reasonably
satisfactory to such indemnified party, and, after notice from the indemnifying
party to such indemnified party of its election to assume and undertake the
defense thereof, the indemnifying party shall not be liable to such indemnified
party under this Section 10(d) for any legal expenses subsequently incurred by
such indemnified party in connection with the defense thereof other than
reasonable costs of investigation; provided, however, that, if the defendants in
any such action include both the indemnified party and the indemnifying party
and the indemnified party shall have reasonably concluded that the interests of
the indemnified party reasonably may be deemed to conflict with the interests of
the indemnifying party, the indemnified party shall have the right to select one
separate counsel and to assume such legal defenses and otherwise to participate
in the defense of such action, with the reasonable expenses and fees of such
separate counsel and other expenses related to such participation to be
reimbursed by the indemnifying party as incurred.

     Notwithstanding the foregoing, any indemnified party shall have the right
to retain its own counsel in any such action, but the reasonable fees and
disbursements of such counsel shall be at the expense of such indemnified party
unless (i) the indemnifying party shall have failed to retain counsel for the
indemnified party as aforesaid, (ii) the indemnified party shall have reasonably
concluded that its interests conflict with the interests of the indemnifying
party, the indemnifying party and such indemnified party shall have mutually
agreed to the retention of such counsel. It is understood that the indemnifying
party shall not, in connection with any action or related actions in the same
jurisdiction, be liable for the fees and disbursements of more than one separate
firm qualified in such jurisdiction to act as counsel for the indemnified party.
The indemnifying party shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent or if
there be a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party from and against any loss or liability by reason
of such settlement or judgment.

     (e)   CONTRIBUTION. In order to provide for just and equitable contribution
in circumstances under which the indemnity contemplated by Section 10(d) is for
any reason not available as a result of a final judicial determination by a
court of competent jurisdiction that such indemnification obligation is
unenforceable in such case, the party which, but for such final

                                      -16-
<Page>

judicial determination of unenforceability would have been required to indemnify
(the "INDEMNIFYING PARTY"), and the party which, but for such final judicial
determination would have been entitled to be indemnified in such circumstances
(the "INDEMNIFIED PARTY") shall contribute to the aggregate losses, liabilities,
claims, damages and expenses of the nature contemplated by such indemnity
agreement incurred by Indemnified Party in such proportion as is appropriate to
reflect the relative fault of the Indemnifying and the Indemnified Parties. The
parties' relative fault shall be determined by reference to, among other things,
whether the claims relate to information provided by or relating to such Party,
each Party's knowledge and access to information concerning the matter with
respect to which the claim was asserted, the opportunity to correct and prevent
any statement or omission and any other equitable considerations appropriate
under the circumstances. The Company and each Person selling securities agree
with each other that no seller of Common Stock shall be required to contribute
any amount in excess of the amount such seller would have been required to pay
to an indemnified party if the indemnity under Section 10(d) were available.

     No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any
person who is not guilty of such fraudulent misrepresentation. The
indemnification of underwriters provided for in this Section 10(d) shall be on
such other terms and conditions as are at the time customary and reasonably
required by such underwriters and the indemnification of the sellers of Warrant
Shares in such underwriting shall, at the sellers' request, be modified to
conform to such terms and conditions.

     (f)   TERMINATION OF REGISTRATION RIGHTS. The right of any Warrantholder or
holder of Warrant Shares to request inclusion in any registration pursuant to
Section 10(a) shall terminate on the earlier of (i) such date after the closing
of the Initial Public Offering of the Company as all Warrant Shares held or
entitled to be held upon conversion by such Warrantholder or holder of Warrant
Shares may immediately be sold under Rule 144(k), and (ii) 2 years after the
closing of the Company's Initial Public Offering.

     SECTION 10.  TRANSFERS OF THE WARRANT.

     (a)   TRANSFER AND EXCHANGES. The Company shall initially record each
Warrant on a register to be maintained by the Company with its other stock books
and, subject to Section 11(b) hereof, from time to time thereafter shall record
a transfer of each Warrant on such register when such Warrant is: (i)
surrendered for transfer in accordance with the terms hereof, (ii) properly
endorsed and accompanied by appropriate instructions, and (iii) accompanied by
payment in cash or by check, bank draft or money order payable to the order of
the Company, in United States currency, of an amount equal to any stamp or other
tax or governmental charge or fee required to be paid in connection with the
transfer thereof. Upon any such transfer, a new Warrant or Warrants shall be
issued to the transferee and the affected Warrantholder (in the event that such
Warrant is only partially transferred) and the surrendered Warrant shall be
canceled. Each such transferee shall succeed to all of the rights of the
transferring Warrantholder under this Agreement or in the event that such
Warrant is only partially transferred, the transferring Warrantholder and such
transferee shall, simultaneously, hold rights hereunder in proportion to their
respective Percentage Interests. Each Warrant may be exchanged at the option of
a Warrantholder, when surrendered at the Principal Office of the Company, for
another

                                      -17-
<Page>

Warrant or other Warrants of like tenor and representing in the aggregate the
right to purchase a like number of shares of Common Stock, subject to adjustment
as more fully set forth herein.

     (b)   TRANSFERS SUBJECT TO SECURITIES LAWS; STOCKHOLDERS AGREEMENT. Subject
to the restrictions set forth in this Section 11 and the provisions of
Section 12, each Warrantholder may at any time and from time to time freely
transfer its Warrant and the Warrant Shares in whole or in part after the
eighteen (18) month anniversary of the date of this Agreement. Prior to the
eighteen (18) month anniversary of the date of this Agreement, no Warrantholder
may transfer the Warrant or the Warrant Shares, in whole or in part, without the
prior written consent of the Company, except as provided in the proviso of the
first paragraph of Section 12(a)(i), and except to an Affiliate of such
Warrantholder who has agreed in writing to be bound by the terms of this
Section 11(b) and Section 12. No Warrant has been, and the Warrant Shares at the
time of their issuance may not be, registered under the Securities Act, and,
except as provided in this Agreement, nothing herein contained shall be deemed
to require the Company to so register any Warrant or Warrant Shares. The
Warrants and the Warrant Shares are issued or issuable subject to the provisions
and conditions contained herein and in the Purchase Agreement, and every
Warrantholder by accepting any Warrant and each transferee of any Warrant or
Warrant Shares, agrees with the Company to such provisions and conditions, and
represents to the Company that such Warrant has been acquired and the Warrant
Shares will be acquired for the account of such Warrantholder for investment and
not with a view to or for sale in connection with any distribution thereof.

     (c)   RESTRICTIVE SECURITIES LEGEND. Each certificate representing the
shares of Common Stock issued upon the exercise of any Warrant shall bear the
restrictive legend set forth below:

     "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS OF ANY STATE AND
MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND REGISTRATION OR
QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN
APPLICABLE EXEMPTION TO THE REGISTRATION AND/OR QUALIFICATION REQUIREMENTS OF
SUCH ACT AND SUCH STATE LAWS."

     SECTION 11.  RIGHT OF FIRST REFUSAL IN SALES BY SECURITY HOLDERS.

     (a)   RIGHT OF FIRST REFUSAL ON SALES.

           (i)    SALES TO THIRD PARTIES. If at any time after the eighteen (18)
month anniversary of the date of this Agreement, a Warrantholder or the holder
of shares received upon the exercise of the Warrant or any other shares of
capital stock into which the shares of Common Stock may be converted (each, a
"SECURITIES HOLDER") desires to transfer all or any part of the Warrant or the
shares of capital stock of the Company beneficially owned by him (the
"SECURITIES") in a privately-negotiated transaction pursuant to a bona fide
offer (the "Proposed Sale") from a third party to the Securities Holder or by
the Securities Holder to a third party (the "PROPOSED TRANSFEREE"), such
Securities Holder shall first submit a written offer (the "OFFER") to

                                      -18-
<Page>

sell such Securities (the "OFFERED SECURITIES") to Hexal Pharmaceuticals, Inc.
or its assignee ("HEXAL") on terms and conditions, including without limitation,
price, not less favorable to Hexal than those on which the offering Securities
Holder proposes to sell such Offered Securities to the Proposed Transferee or
otherwise pursuant to the Proposed Sale; provided, however, that the
requirements set forth in this Section 12(a)(i) shall not apply to any Proposed
Sale if the Proposed Transferee in such Proposed Sale is an Affiliate or
stockholder of the offering Securities Holder, any general or limited partner or
retired partner, or any stockholder, officer, director or employee thereof, or
any Affiliate of any such person, including, without limitation, members of the
immediate family, irrevocable trusts for estate planning purposes and personal
representatives thereof who shall agree in writing with the Company to be bound
by the terms of Section 11 and this Section 12.

     The Offer shall disclose the identity of the Proposed Transferee, and the
terms of the Proposed Sale, the number of Offered Securities proposed to be
sold, the total number of Securities owned by the offering Securities Holder,
the terms and conditions, including without limitation, price, of the Proposed
Sale, and any other material facts relating to the Proposed Sale which may be
requested by Hexal. The offer shall further state that Hexal or its assignees
may acquire, in accordance with the provisions of this Agreement, all or any
portion of the Offered Securities for the price indicated in the Offer and upon
the other terms and conditions, including, without limitation, deferred or
installment payment (if applicable), set forth therein.

     Additionally, each Securities Holder agrees not to make any Proposed Sale
to any competitor of the Company or any of its Affiliates without the prior
written consent of Hexal.

           (ii)   HEXAL'S RIGHT OF FIRST REFUSAL. Upon receipt of the Offer, if
Hexal or its assignees desires to purchase all, but not less than all, of the
Offered Securities, Hexal shall so indicate by delivering a written notice of
its election to purchase such shares to the offering Securities Holder, which
notice shall be delivered in person not later than ten (10) days following the
date on which Hexal received the Offer. Such notice shall, when taken in
conjunction with the Offer, be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of such Offered Shares to Hexal
or its assignees on the terms of the Offer. The closing of the sale of the
Offered Securities to Hexal pursuant to this clause (ii) of Section 12(a) shall
be made at the offices of the Company on such date as may be agreed upon by the
Company and the offering Securities Holder, but no later than the 30th day
following the date the Offer is received by Hexal. Such sale shall be effected
by the offering Securities Holder's delivery to Hexal of a certificate(s)
evidencing the Offered Securities (or any portion thereof) to be purchased by
Hexal or its assignees, duly endorsed for transfer to Hexal or its assignees,
against payment to the offering Securities Holder of the purchase price by Hexal
or its assignees. The exercise or non-exercise by Hexal of its rights pursuant
to this clause (ii) of Section 12(a), shall be without prejudice to its rights
under this clause (ii) of Section 12(a) with respect to any future sales of
Offered Securities.

           (iii)  SALES TO PROPOSED TRANSFEREE. If Hexal and/or its assignees do
not purchase all of the Offered Securities, the Offered Securities may be sold
by the offering Securities Holder, at any time after the 15th day, but not later
than the 60th day, after the date the Offer was made, pursuant to the Proposed
Sale. Any such sale shall be at the same price and upon other terms and
conditions, if any, not more favorable to the transferee than those specified

                                      -19-
<Page>

in the Offer. Any Offered Securities not sold prior to the expiration of such
60-day period, shall continue to be subject to the requirements of a prior offer
and right of first refusal pursuant to this Section 12(a).

     (b)   ALTERATION OF TERMS OF OFFER. For the purposes of Section 12(a), if
either the offering Securities Holder or the Proposed Transferee proposes to
alter any material terms or conditions, including, without limitation, the
price, of the Offer, such alteration shall be deemed a cancellation of the Offer
and shall require the issuance of a new offer on the terms and conditions
proposed in such alteration. The provisions of this Section 12, including,
without limitation, subsection (a) thereof, shall apply to such new offer.

     (c)   TERM. This Section 12 shall terminate upon the consummation of an
Initial Public Offering.

     (d)   TRANSFER OF SECURITIES BY STOCKHOLDERS. Notwithstanding anything to
the contrary contained in this Agreement, no Securities Holder shall sell,
transfer, or dispose of Securities owned by it, and each such sale, transfer, or
disposition shall be null and void, unless the transferee of such Securities
executes a counterpart of this Agreement, or otherwise agrees in writing to be
bound by all of the provisions hereof.

     COME ALONG. Prior to the Company's Initial Public Offering, neither Hexal
nor a Permitted Hexal Transferee (as defined below) (each, a "HEXAL SELLER")
shall sell, dispose of or otherwise transfer (collectively, a "DISPOSITION") any
shares of the Company's Capital Stock to any Person (a "THIRD PARTY
TRANSFEREE"), other than to a Permitted Hexal Transferee, except in a
transaction that complies with this Section 13. As used herein, a "PERMITTED
HEXAL TRANSFEREE" means an Affiliate of Hexal to when a Disposition of shares of
the Company's Capital Stock has been made, that has agreed to be bound as a
Hexal Seller by the terms of this Section 13.

     (e)   COME ALONG. Each Hexal Seller shall permit each holder of Warrant
Securities, or cause each holder of Warrant Securities to be permitted, to sell
all or any part of the Warrant Shares held by or issuable to him, her or it for
the same consideration per share and otherwise on the same terms and as those
applicable to the sale by the Hexal Seller of its shares (calculated in the case
of the Preferred Stock held by the Hexal Seller, on an as-if converted basis).
To the extent one or more of the holders of Warrant Securities exercise such
right of participation and the transferee limits the number of shares it
purchases, the number of shares of the Company's Preferred Stock (or Common
Stock) which the Hexal Seller may sell in such Disposition shall be
correspondingly reduced (calculated in the case of the Preferred Stock held by
the Hexal Seller, on an as-if converted basis). Each Hexal Seller's and each
holder of Warrant Securities' pro rata share shall be the ratio of the number of
shares of Common Stock issued and held by such Person (on an as-if converted and
as-if exercised basis) as of the date of the offer to the sum of the total
number of shares of Common Stock issued and held by all exercising holders of
Warrant Securities and all Hexal Sellers, as a group (on an as-if converted and
as-if exercised basis) as of such date.

     (f)   NOTICE. Hexal's obligation under this Section 13 to afford the
holders of Warrant Securities, or cause the holders of Warrant Securities to be
afforded, the rights referred to herein will be discharged if the holders of
Warrant Securities are given written notice which allows

                                      -20-
<Page>

such holders thirty (30) days to elect to avail themselves of such rights by a
written reply, addressed to such Person as may be designated in the notice and,
if requested in such notice, sent by registered mail, return receipt requested.
If a Third Party Purchaser fails to purchase any shares from a holder of Warrant
Securities who has properly exercised its come-along rights pursuant to this
Section 13 (other than shares not purchased as a result of the pro-rata cut back
mechanism described in subsection (a) of this Section 13, then the Hexal Seller
shall not be permitted to consummate its proposed sale to the Third Party
Purchaser, and any such attempted sale shall be null and void AB INITIO and the
Company shall not register any purported Disposition of the shares resulting
therefrom.

     (g)   NO IMPAIRMENT. No Hexal Seller will Dispose of its interest in any
Person that directly or indirectly controls the Company for the purpose of
avoiding or seeking to avoid the observance or performance of the terms of this
Section 13.

     CONFIDENTIALITY. Each Securities Holder agrees that it shall, and shall
cause each of its officers, directors, stockholders, employees, agents and
representatives to, keep confidential and will not disclose or divulge any
confidential, proprietary or trade secret type information which such Securities
Holder may obtain from the Company pursuant to financial statements, reports and
other materials submitted by the Company to such Securities Holder pursuant to
financial statements, reports and other materials submitted by the Company to
such Securities Holder pursuant to this Agreement, or pursuant to visitation or
inspection rights granted hereunder, unless such information is known, or until
such information becomes known, to the public; provided, however, that a
Securities Holder may disclose such information (a) on a confidential basis to
its attorneys, accountants, consultants and other professionals to the extent
necessary to obtain their services in connection with its investment in the
Company, (b) to any affiliate or partner of such Securities Holder, and (c) as
required by regulatory authority or applicable law.

     DELAYS, OMISSIONS AND INDULGENCES. No delay or omission to exercise any
right, power or remedy accruing to any Warrantholder upon any breach or default
of the Company hereunder or under any Warrant shall impair any such right, power
or remedy, nor shall it be construed to be a waiver of any such breach or
default, or any acquiescence therein, or of or in any similar breach or default
thereafter occurring; nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on
any Warrantholder's part of any breach or default hereunder or under any
Warrant, or any waiver on any Warrantholder's part of any provisions or
conditions hereof or of any Warrant must be in writing and that all remedies,
either hereunder, under any Warrant or by law or otherwise afforded to the
Warrantholders, shall be cumulative and not alternative.

     RIGHTS OF TRANSFEREES. The rights and obligations of the Warrantholders
hereunder and under each Warrant shall pass to and inure to the benefit of all
subsequent transferees of all or any portion of a Warrant or Warrant Shares
(provided that each Warrantholder and any transferee shall hold such rights in
proportion to their respective ownership of the Warrants and Warrant Shares)
until extinguished pursuant to the terms hereof, provided that the rights set
forth in Section 10 may be transferred or assigned only to a transferee or
assignee of not less than 5,000 Warrant Shares, as adjusted for stock splits,
stock dividends or other like recapitalization events after the date hereof.

                                      -21-
<Page>

     CAPTIONS. The titles and captions of the Sections and other provisions
hereof are for convenience of reference only and are not to be considered in
construing this Agreement.

     NOTICES. All notices, demands and other communications provided for or
permitted hereunder shall be made in writing and shall be by registered or
certified first-class mail, return receipt requested, telecopy, overnight
courier service or personal delivery:

     (a)   if to the Company or Hexal:

           Eon Labs Manufacturing, Inc.
           227-15 North Conduit Avenue
           Laurelton, NY 11413
           Attention:   William F. Holt
           Telecopy:    (718) 276-1735

     (b)   if to any Warrantholder, to the respective address set forth on the
           corporate records of the Company.

All such notices and communications shall be deemed to have been duly given:
when delivered by hand, if personally delivered; when delivered by courier, if
delivered by commercial overnight courier service; five (5) Business Days after
being deposited in the mail, postage prepaid, if mailed; and when receipt is
acknowledged, if telecopied.

     SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and assigns,
provided that the Company shall have no right to assign its rights, or to
delegate its obligations, hereunder without the prior written consent of each
Warrantholder.

     SEVERABILITY. If any one or more of the provisions contained herein, or the
application thereof in any circumstance, is held invalid, illegal or
unenforceable in any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and of the remaining
provisions hereof shall not be in any way impaired, unless the provisions held
invalid, illegal or unenforceable shall substantially impair the benefits of the
remaining provisions hereof.

     GOVERNING LAW. THIS AGREEMENT AND EACH WARRANT IS TO BE CONSTRUED AND
ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK
AND WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW OF SUCH STATE.

     ENTIRE AGREEMENT; AMENDMENT. This Agreement, the Warrant and the Purchase
Agreement are intended by the parties as a final expression of their agreement
and are intended to be a complete and exclusive statement of the agreement and
understanding of the parties hereto in respect of the subject matter contained
herein and therein. Except as otherwise expressly provided in this Agreement,
any provision of this Agreement or of any Warrant may be amended or modified
only by an instrument in writing signed by the Company and the Required
Warrantholders.

                                      -22-
<Page>

     RULES OF CONSTRUCTION. Unless the context otherwise requires "or" is not
exclusive, and references to sections or subsections refer to sections or
subsections of this Agreement. All pronouns and any variations thereof refer to
the masculine, feminine or neuter, singular or plural, as the context may
require.

                                      * * *

                                      -23-
<Page>

     IN WITNESS WHEREOF, each party hereto has caused this Agreement to be duly
executed as of the date first above written.

                                    EON LABS MANUFACTURING, INC.

                                    By: /s/ William F. Holt
                                        ----------------------------------------
                                        Name:  William F. Holt
                                               ---------------------------------
                                        Title: Vice President - Finance
                                               ---------------------------------

                                    WARRANTHOLDERS:

                                    J.H. WHITNEY & CO.

                                    By:  /s/ Daniel J. O'Brien
                                         ---------------------------------------

                                    WHITNEY 1990 EQUITY FUND, L.P.

                                    By:  /s/ Daniel J. O'Brien
                                         ---------------------------------------

                                    CITICORP VENTURE CAPITAL, LTD.

                                    By:  /s/ Rick Mayberry
                                         ---------------------------------------

                                    CANAAN CAPITAL OFFSHORE LIMITED
                                         PARTNERSHIP, C.V.

                                    By:  /s/ Stephen L. Green
                                         ---------------------------------------

                                    CANAAN CAPITAL LIMITED PARTNERSHIP

                                    By:  /s/ Stephen L. Green
                                         ---------------------------------------

                                      -24-
<Page>

                                    QAUI, LTD.

                                    By:  /s/ Ariane Slinger
                                         ---------------------------------------

                                         /s/ Jacqueline Nabin
                                         ---------------------------------------

                                    /s/ Jeffry R. Ray
                                    --------------------------------------------
                                    Jeffrey R. Jay

                                    /s/ Stephen C. Sherrill
                                    --------------------------------------------
                                    Stephen C.  Sherrill

                                    /s/ Bruce C. Bruckmann
                                    --------------------------------------------
                                    Bruce C. Bruckmann

                                    /s/ Richard M. Cashin
                                    --------------------------------------------
                                    Richard M. Cashin

                                    /s/ Jeanne Blasberg
                                    --------------------------------------------
                                    Jeanne Blasberg, Trustee of The Thomas F.
                                    McWilliams Flint Trust dated 10/27/98

                                    /s/ David F. Thomas
                                    --------------------------------------------
                                    David F. Thomas

                                    /s/ Harold O. Rosser
                                    --------------------------------------------
                                    Harold O. Rosser

                                    SOLELY FOR THE PURPOSE OF SECTION 13
                                    HEREOF:
                                    HEXAL PHARMACEUTICALS, INC.

                                    By:  /s/ Werner Leppla
                                         ---------------------------------------

                                      -25-
<Page>

                                    EXHIBIT A

                                 FORM OF WARRANT

         THIS STOCK PURCHASE WARRANT AND THE SHARES THAT MAY BE PURCHASED
         HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
         UNDER THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED
         OR OTHERWISE DISPOSED OR EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
         STATEMENT UNDER SUCH ACT AND REGISTRATION OR QUALIFICATION UNDER
         APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION
         TO THE REGISTRATION AND/OR QUALIFICATION REQUIREMENTS OF SUCH ACT AND
         SUCH STATE LAWS.

                          EON LABS MANUFACTURING, INC.

                             STOCK PURCHASE WARRANT

Number _________

     THIS IS TO CERTIFY that [_______________], and its transferees, successors
and assigns (the "WARRANTHOLDER"), for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, is entitled to
purchase from EON LABS MANUFACTURING, INC., a Delaware corporation (the
"COMPANY"), subject to the terms and conditions of the Warrant Agreement, dated
as of December 5, 2000 (as amended or otherwise modified, the "WARRANT
AGREEMENT"), between the Company and the other parties thereto, at a price per
share equal to the Exercise Price, that number of fully paid and nonassessable
share of the Company's Common Stock as are equal to __% (the "ASSIGNED
PERCENTAGE") of the Company's Fully Diluted Common Stock. Capitalized terms used
herein shall have the meanings ascribed to such terms in Section 1 of the
Warrant Agreement.

     Payment of the Exercise Price may be made as set forth in Section 3 of the
Warrant Agreement.

     If this Warrant is not exercised on or before 5:00 p.m., New York City time
on the Expiration Date, this Warrant shall become void and all rights hereunder
shall cease as of such time, except as provided in the Warrant Agreement.

     This Warrant is one of the Warrants issued pursuant to the Warrant
Agreement and is subject to, and entitled to the benefits of, all of the terms,
provisions and conditions of the Warrant Agreement, which Warrant Agreement is
hereby incorporated by reference herein and made a part hereof. The Warrant
Agreement sets forth a full description of the rights, limitations of rights,
obligations, duties and immunities of the Company and the Warrantholder with
respect to this Warrant. Copies of the Warrant Agreement are on file at the
Principal Office of the Company.

<Page>

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed in its
name by its duly authorized officer, as of the __ day of [____________].

                                    EON LABS MANUFACTURING, INC.

                                    By:
                                        ----------------------------------------
                                           Name:
                                           Title:

<Page>

                                    EXHIBIT B

                           FORM OF NOTICE OF EXERCISE

_______________, ____

To:      Eon Labs Manufacturing, Inc.
         227-15 North Conduit Avenue
         Laurelton, NY  11413
         Attention:  William F. Holt
         Telecopy:

     1.    The undersigned, pursuant to the provisions of the attached Warrant,
hereby elects to exercise such Warrant with respect to ___ shares of Common
Stock (the "EXERCISE AMOUNT"). Capitalized terms used but not otherwise defined
herein have the meanings ascribed thereto in the attached Warrant.

     2.    The undersigned herewith tenders payment for such shares in the
following manner (please check type, or types, of payment and indicate the
portion of the Exercise Price to be paid by each type of payment):

            ____     Exercise for Cash
            ____     Cashless Exercise

     3.    Please issue a certificate or certificates representing the shares
issuable in respect hereof under the terms of the attached Warrant, as follows:

                    (Name of Record Warrantholder/Transferee)

and deliver such certificate or certificates to the following address:

                  (Address of Record Warrantholder/Transferee)

     4.    The undersigned represents that the aforesaid shares are being
acquired for the account of the undersigned for investment and not with a view
to, or for resale in connection with, the distribution thereof and that the
undersigned has no present intention of distributing or reselling such shares.

<Page>

     5.    If the Exercise Amount is less than all of the shares of Common Stock
purchasable hereunder, please issue a new warrant representing the remaining
balance of such shares, as follows:

                    (Name of Record Warrantholder/Transferee)

and deliver such warrant to the following address:

                  (Address of Record Warrantholder/Transferee)

     IN WITNESS WHEREOF, the undersigned Warrantholder has caused this Notice of
Exercise to be executed as of this ___ day of ____________, ____.

                                    (Name of Warrantholder)

                                    By:
                                        ----------------------------------------<Page>

                                                                  Exhibit 10.11

                            PRODUCT ROYALTY AGREEMENT

                  PRODUCT ROYALTY AGREEMENT, dated as of March 20, 2002, by
and between HEXAL AG, a German company ("Hexal") and EON LABS, INC., a
Delaware corporation ("Eon").

                              W I T N E S S E T H :

                  WHEREAS, Hexal is engaged in the business of developing,
manufacturing and selling pharmaceutical products outside of the Territory
(as defined below);

                  WHEREAS, Eon is engaged in the business of developing,
manufacturing and selling pharmaceutical products in the Territory;

                  WHEREAS, Hexal has provided Eon with access to the Hexal
File (as defined below), which Eon has used in connection with the
formulation and development of cyclosporin 25 mg. and 100 mg. softgel
capsules (the "Products"), and the preparation and filing with the U.S. Food
and Drug Administration ("FDA") of Abbreviated New Drug Applications
("ANDAs") to manufacture and sell the Products;

                  WHEREAS, the parties desire to enter into this Agreement to
set forth the terms and conditions under which Eon will have access to the
Hexal File and will make royalty payments to Hexal with respect to Eon's
sales of the Products.

                  NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, and in
consideration of the mutual promises contained herein, Hexal and Eon hereby
agree as follows:

         1.       HEXAL FILE.

                  (a)      Effective as of January 11, 1999 (the "Effective
Date"), Hexal hereby grants to Eon and its sublicensees an exclusive and
perpetual license (the "License") to use the Hexal File in connection with
the development and manufacture of the Products pursuant to the ANDAs and the
sale of the Products in the United States and its territories and possessions
(the "Territory").

                  (b)      The term "Hexal File" shall mean the formulation
and all supporting technology, regulatory dossiers, technical information,
manufacturing processes and other know-how and intellectual property rights,
including the patents listed on SCHEDULE A hereto, relating to cyclosporin
and with respect to which Hexal now has, or hereafter obtains, any right,
title or interest.

                  (c)      Hexal agrees that it will cooperate with Eon in
connection with Eon's use of the Hexal File in the development and manufacture
of the Products and that it will make its personnel available to Eon to assist
it in adapting the information contained in the Hexal File for use by Eon in
developing and manufacturing the Products. Eon agrees that it shall bear the
respective cost of any personnel provided by Hexal. Any ANDAs with respect to
the products shall be filed by Eon and issued in Eon's name. Eon agrees that it
will provide Hexal, at no

<Page>

charge to Hexal, with access to Eon's research and development and
manufacturing files with respect to the Products in connection with Hexal's
development and manufacturing of the Products for sale outside the Territory.

                  (d)      Hexal agrees that so long as the License shall be
in effect, it will not, directly or indirectly, (i) develop or manufacture
any other cyclosporin product for sale in the Territory, (ii) sell any other
cyclosporin product in the Territory, or (iii) authorize or license any third
party, to do any of the foregoing, without first negotiating with Eon over
terms for Eon to acquire rights with respect to such product similar to its
rights under this Agreement with respect to the Products.

         2.       ROYALTY PAYMENTS.

                  (a)      In consideration for the License and the rights to
use the Hexal File, Eon agrees to pay Hexal a royalty (the "Royalty") in an
amount equal to the applicable Royalty Rate (as defined below) of any Gross
Margin (as defined below) from all sales of the Products by Eon from and
after the Effective Date; provided, however, that (i) fifty percent (50%) of
Eon's Development Costs (as defined below) may be deducted by Eon from the
Royalty payments due hereunder and (ii) fifty percent (50%) of Eon's Legal
Fees (as defined below). The Royalty Rate and Gross Margin shall be
determined for each calendar quarter in which Eon makes sales of the
Products, and Eon shall pay any Royalty due to Hexal within 45 days following
the end of each such calendar quarter.

                  (b)      For the purposes of this Agreement, the following
definitions shall apply:

                           (A)      "Gross Margin" shall mean Net Sales less
                                    Cost of Goods.

                           (B)      "Net Sales" shall mean Eon's gross sales of
                                    the Products less shipping costs (based on
                                    weight and distance), commissions, trade
                                    discounts, chargebacks, terms (e.g., cash
                                    discounts such as 2% 30 days),
                                    administrative fees, credits or allowances,
                                    including those granted on account of price
                                    adjustments (including inventory and price
                                    protection) related to market forces,
                                    returns and rebates (including Medicaid), if
                                    any incurred or granted, determined in
                                    accordance with generally accepted
                                    accounting principles consistently applied.

                           (C)      "Cost of Goods" shall mean 100% of Eon's
                                    fully absorbed standard cost of
                                    manufacturing, finishing, packaging,
                                    labeling and shipping the Products,
                                    including administrative costs and costs of
                                    testing and controls (such as quality
                                    assurance/quality control costs)
                                    attributable to the Products, determined in
                                    accordance with generally accepted
                                    accounting principles consistently applied.

                           (D)      "Development Costs" shall mean all of Eon's
                                    (i) research and development costs allocated
                                    to the Products, determined in accordance
                                    with generally accepted accounting
                                    principles consistently applied, including
                                    without limitation the costs of any

                                      -2-
<Page>

                                    biostudies and clinical trials conducted
                                    with respect to the Products, and (ii) any
                                    and all costs, liabilities, damages and
                                    expenses (including attorney's fees) arising
                                    directly or indirectly as a result of any
                                    claim by a third party that Eon's
                                    development, manufacture and/or sale of the
                                    Products and/or use of any aspect of the
                                    Hexal File infringes any patent or other
                                    intellectual property rights of such third
                                    party.

                           (E)      "Gross Margin Percentage" shall mean (1)
                                    gross sales of the Products less Cost of
                                    Goods of such Products from such calendar
                                    quarter in question divided by (2) gross
                                    sales of the Products for the calendar
                                    quarter in question.

                           (F)      "Legal Fees" shall mean all costs incurred
                                    by Eon in connection with its defense of any
                                    lawsuits brought against it in connection
                                    with its development, manufacture and sale
                                    of the Products.

                           (G)      "Royalty Rate" shall mean twenty percent
                                    (20%), subject to reduction as set forth
                                    below:

                                    (1)     If the Gross Margin Percentage is
                                            less than sixty percent (60%) for
                                            the calendar quarter in question,
                                            the Royalty Rate shall be reduced by
                                            one half (1/2) of the difference
                                            between sixty percent (60%) and the
                                            actual Gross Margin Percentage for
                                            such calendar quarter; and

                                    (2)     If for the immediately preceding
                                            calendar quarter, the gross sales of
                                            the Products for such quarter
                                            exceeds the Net Sales for such
                                            quarter by more than twenty percent
                                            (20%), then the Royalty Rate shall
                                            be further reduced by one half (1/2)
                                            of the excess above twenty percent
                                            (20%).

                  (c)      Quarterly Reports. Within 45 days after the end of
each calendar quarter in which sales of the product are made by Eon, Eon
shall deliver to Hexal a statement setting forth: (A) the Net Sales of the
Products during such quarter; (B) the Cost of Goods for such Products; (C)
the Gross Margin and Gross Margin Percentage for such Products for such
quarter; (D) the Legal Fees for such quarter; and (E) the calculation of the
Royalty Rate and any Royalty payable with respect to such quarter.

                  (d)      Access, Disagreements. Eon shall provide Hexal's
independent certified public accountants with access, during regular business
hours and upon reasonable prior notice, and subject to the confidentiality
undertakings contained in this Agreement, to Eon's books and records relating
to Cost of Goods, Net Sales, Development Costs and Legal Fees solely for
purposes of verifying the accuracy of the calculations of Gross Margin and
Royalty payments. If any such verification shows any underpayment or
overpayment, a correcting payment or a refund, together with interest at the
current prime lending rate established by leading New York banks as published
in The Wall Street Journal, shall be made within (30) days of completion of

                                      -3-
<Page>

such verification and submission of the results thereof, with details of the
calculations included therein. If either party disagrees in any respect with
results of such verification, Hexal and Eon shall use their good faith best
efforts to resolve the disagreement. If they are unable within 45 days to
reach a resolution, Eon and Hexal shall jointly retain an independent auditor
to review the determination of Gross Margin and Royalty payments and the
verification conducted as provided above. The decision of such independent
auditor with respect to the payments if any, to be made pursuant to this
Section shall be final and binding on the parties. The costs of such
independent auditor shall be borne by the parties in inverse proportion to
the extent to which the auditor's determination supports such party's
position.

         3.       CONFIDENTIALITY.

                  (a)      As used herein, the term "Confidential
Information" shall mean any information pertaining to the Hexal File and/or
the development, manufacture, marketing and sale of the Products from time to
time communicated by or on behalf of Eon to Hexal, or by or on behalf of
Hexal to Eon, as the case may be, including without limitation, trade
secrets, business methods, pricing, costs, suppliers, manufacturing and
customer information, whether of a written, oral or visual nature. The
Confidential Information shall be treated by Eon and Hexal, respectively, as
confidential, and shall not be disclosed or revealed to any third party and
shall only be used in connection with the performance of this Agreement;
provided, however, that Confidential Information shall not include
information that the receiving party can document as having been:

                           (i)      public knowledge prior to the disclosure,
or which hereafter becomes public knowledge through no fault of the receiving
party;

                           (ii)     lawfully in its possession prior to the
time of disclosure; or

                           (iii)    received, after the time of disclosure,
from a third party not under a similar obligation of confidentiality to the
other party.

                  This Agreement shall not prohibit disclosures of
Confidential Information required to be made (A) pursuant to any order of any
court having jurisdiction and power to order such information to be released
or made public; or (B) to any governmental or regulatory agency pursuant to
applicable laws and regulations.

                  (b)      Each party shall take all such precautions as it
normally takes with its own Confidential Information to prevent any improper
disclosure. Each party shall restrict the Confidential Information of the
other to its agents, employees and representatives who are directly involved
in the performance and enforcement of this Agreement to the extent that they
have need of such, and then only on a confidential basis.

                  (c)      If either party shall breach any of the provisions
of this Section 3, in addition to and without limiting any other remedies
available to such party at law or in equity, the other party shall be
entitled to immediate injunctive relief in any court to restrain any such
breach or threatened breach and to enforce the provisions of this Section 3.
The parties acknowledge and agree that there is no adequate remedy at law for
any such breach or threatened

                                      -4-
<Page>

breach and, in the event that any proceeding is brought seeking injunctive
relief, the parties shall not use as a defense thereto that there is an
adequate remedy at law.

         4.       ASSIGNMENT. This Agreement shall inure to the benefit of,
and shall be binding upon each of, the parties hereto and their respective
successors and assigns. This Agreement may not be assigned in whole or in
part by either party without the prior written consent of the other;
provided, however, that Hexal or Eon may, without the prior written consent
of the other, assign this Agreement (a) to an affiliate of such party or (b)
in connection with a merger or sale of all or substantially all of the assets
of Eon or Hexal, as the case may be.

         5.       NOTICES. All communications under this Agreement shall be
in writing and shall be delivered by hand or facsimile or mailed by overnight
courier or by registered or certified mail, postage prepaid:

                  (a)      if to Hexal, at Industriestrasse 25, 83607
Holzkirchen, Germany, marked for the attention of Thomas Strungmann,
facsimile +49 8024 908 116, or at such other address as Hexal may have
furnished Eon in writing; and

                  (b)      if to Eon, at 227-15 North Conduit Avenue,
Laurelton, New York, 11413, marked for the attention of President, facsimile:
(718) 276-1735, or at such other address as Eon may have furnished Hexal in
writing.

                  Any notice so addressed shall be deemed to be given: if
delivered by hand or facsimile, on the date of such delivery; if mailed by
courier, on the first business day following the date of such mailing; and if
mailed by registered or certified mail, on the third business day after the
date of such mailing; except in case of common proof of late arrival of such
notice.

         6.       GOVERNING LAW; VENUE. This Agreement shall be governed by
and construed in accordance with the laws of Germany. Jurisdiction for
disputes brought under this Agreement shall be Landgericht Muenchen II.

         7.       AMENDMENT AND WAIVER. This Agreement may be amended,
modified, superseded, canceled, and any other of the terms or conditions
hereof may be modified, only by a written instrument executed by both parties
hereto or, in the case of a waiver, by the party waiving compliance. Failure
of any party at any time or times to require performance of any provision
hereof shall in no manner affect the right of such party at a later time to
enforce the same, and no waiver of any nature, whether by conduct or
otherwise, in any one or more instances, shall be deemed to be or considered
as a further or continuing waiver of any other provision of this Agreement.

         8.       ENTIRE AGREEMENT. This Agreement, together with the
Exhibits hereto, contains the entire agreement between the parties hereto and
supersedes any agreements between them with respect to the subject matter
hereof

         9.       SECTION HEADINGS. The section headings contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.

                                      -5-
<Page>

         10.      COUNTERPARTS. This Agreement may be executed in any number
of separate counterparts, each of which shall be deemed to be an original,
but which together shall constitute one and the same instrument.

                                      -6-
<Page>

                  IN WITNESS WHEREOF, Hexal and Eon have caused this
Agreement to be duly executed and delivered as of the date first above
written.

                               HEXAL AG

                               By: /s/ Thomas Strungmann
                                  ----------------------------------------------
                                    Name:  Thomas Strungmann
                                    Title: Co-President and Co-Chief Executive
                                           Officer

                               EON LABS, INC.

                               By: /s/ Bernhard Hampl, Ph.D.
                                  ----------------------------------------------
                                    Name:  Bernhard Hampl, Ph.D.
                                    Title: President and Chief Executive Office

                                      -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]